Key Points Addex Therapeutics appointed Jean-Philippe Rocher as Head of Pharmaceutical Development and a member of its executive management team. Rocher brings more than 30…
October 02, 2026
September 30, 2026
Capricor Shares Rise as Longer-Term Deramiocel Data Enter FDA Review
Key Points Capricor shares rose in early trading Tuesday after a World Muscle Society poster on 24-month deramiocel data became available. The analysis follows patients…
September 29, 2026
Corbus Pharmaceuticals Doses First Patient in Registrational CRB-701 Throat Cancer Trial
Key Points TEMPO-1 is a randomized study expected to enroll 250 patients with second-line or later OPSCC. The trial will compare CRB-701 with the investigator’s…
September 29, 2026
Vivos Therapeutics Targets $3.6 Million in Annual Cost Savings as Revenue Initiatives Advance
Key Points for VVOS Investors Vivos expects the full effect of its cost reductions to take hold in the fourth quarter of 2026, with additional…
Key Points TIRC and PsyLabs aim to sign a definitive agreement by November 30, 2026. If they do not, the binding term sheet will lapse….
September 28, 2026
Daré Bioscience Adds U.S. Patent Protection for DARE-HPV as Phase 2 Trial Advances
Key Points Daré Bioscience announced a new U.S. patent covering topical lopinavir-and-ritonavir formulations for HPV-related cervical conditions. Daré holds an exclusive U.S. license to the…
September 24, 2026
Nuvectis’ NXP200 Receives China Breakthrough Therapy Designation for BRAF V600-Mutant High-Grade Glioma
Key Points Nuvectis Pharma said China’s Center for Drug Evaluation granted Breakthrough Therapy Designation to NXP200 for recurrent or progressive BRAF V600-mutant high-grade glioma. NXP200,…
Key Points Vistagen Therapeutics presented exploratory fasedienol data at Psych Congress 2026 in New Orleans. The analyses focused on participants with very severe social anxiety…
September 17, 2026
Clearmind Medicine Presents Non-Hallucinogenic Psychedelic Research at FDA Hearing
Key Points Clearmind Medicine’s Chief of Global Impact, Mary-Elizabeth Gifford, testified at the FDA’s September 14 hearing on the potential future therapeutic use of psychedelic…
September 17, 2026
Aethlon Medical Merges With North Immunology to Advance NOR-101 for Atopic Dermatitis
Key Points Aethlon Medical will merge with privately held North Immunology in an all-stock transaction. The combined company will operate as North Immunology, Inc. and is expected…
Key Points Alzamend Neuro has regained compliance with Nasdaq’s continued-listing requirements. The company reported stockholders’ equity of approximately $5.8 million as of July 31, 2026,…
September 15, 2026
Enveric Secures New U.S. Patent Allowance for Non-Hallucinogenic PTSD Drug Candidates
Key Points Enveric Biosciences received a Notice of Allowance from the U.S. Patent and Trademark Office for compounds in its EVM401 drug-candidate series. The allowance…